Renata expands US portfolio with rosuvastatin launch

Renata PLC is excited to announce the successful shipment of its first consignment of Rosuvastatin to the U.S. market.

Manufactured at Renata's US FDA-approved facility in Bangladesh, Renata's product - better known by its brand name Rolip- is one of the leading and most trusted brands in the Bangladesh market for Rosuvastatin.

Rolip will now be available in the U.S. market as a bioequivalent and interchangeable formulation to the innovator product, offering American patients a practical, affordable, and high-quality alternative for cholesterol management, with identical quality and effectiveness to the original.

Rolip is available in dosage strengths of 5 mg, 10 mg, 20 mg, and 40 mg tablets. This range ensures comprehensive treatment options for patients managing high cholesterol levels. As part of its launching campaign, Renata supplies 8,000,000 units across various strengths, aiming to meet the growing demand for affordable, high-quality cholesterol management solutions.

This event marks another incredible milestone for Renata in expanding its international presence and supporting the global fight against cardiovascular diseases. Rolip joins Renata's mission of delivering an extensive portfolio of high-quality, bioequivalent generic medicines globally, in Bangladesh and beyond.